AI Article Synopsis

  • The Living with Pulmonary Fibrosis questionnaire (L-PF) evaluates the impact of dyspnea on quality of life (QOL) in patients with fibrotic hypersensitivity pneumonitis (FHP), though it hasn't been specifically validated for this group yet.
  • Data from the Pirfenidone in FHP trial showed that the L-PF-35 Dyspnea domain score has good internal consistency and significant correlations with other validated measures, indicating its reliability and responsiveness.
  • The study estimates a meaningful within-patient change (MWPC) threshold for worsening dyspnea at 6.6 points, suggesting the L-PF-35 Dyspnea domain is a useful tool for assessing symptoms in FHP, but further validation

Article Abstract

Background: Dyspnea impairs quality of life (QOL) in patients with fibrotic hypersensitivity pneumonitis (FHP). The Living with Pulmonary Fibrosis questionnaire (L-PF) assesses symptoms, their impacts and PF-related QOL in patients with any form of PF. Its scores have not undergone validation analyses in an FHP cohort.

Methods: We used data from the Pirfenidone in FHP trial to examine reliability, validity and responsiveness of the L-PF-35 Dyspnea domain score (Dyspnea) and to estimate its meaningful within-patient change (MWPC) threshold for worsening. Lack of suitable anchors precluded conducting analyses for other L-PF-35 scores.

Results: At baseline, Dyspnea's internal consistency (Cronbach's coefficient alpha) was 0.85; there were significant correlations with all four anchors (University of California San Diego Shortness of Breath Questionnaire scores r = 0.81, St. George's Activity domain score r = 0.82, percent predicted forced vital capacity r = 0.37, and percent predicted diffusing capacity of the lung for carbon monoxide r = 0.37). Dyspnea was significantly different between anchor subgroups (e.g., lowest percent predicted forced vital capacity (FVC%) vs. highest, 33.5 ± 18.5 vs. 11.1 ± 9.8, p = 0.01). There were significant correlations between changes in Dyspnea and changes in anchor scores at all trial time points. Longitudinal models further confirmed responsiveness. The MWPC threshold estimate for worsening was 6.6 points (range 5-8).

Conclusion: The L-PF-35 Dyspnea domain appears to possess acceptable psychometric properties for assessing dyspnea in patients with FHP. Because instrument validation is never accomplished with one study, additional research is needed to build on the foundation these analyses provide.

Trial Registration: The data for the analyses presented in this manuscript were generated in a trial registered on ClinicalTrials.gov; the identifier was NCT02958917.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11031991PMC
http://dx.doi.org/10.1186/s12890-024-02991-1DOI Listing

Publication Analysis

Top Keywords

l-pf-35 dyspnea
12
dyspnea domain
12
percent predicted
12
reliability validity
8
validity responsiveness
8
responsiveness l-pf-35
8
dyspnea
8
fibrotic hypersensitivity
8
hypersensitivity pneumonitis
8
qol patients
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!